(Boursier.com) — OSE Immunotherapeutics and AbbVie announce a strategic partnership to develop OSE-230, a monoclonal antibody in preclinical development, for the resolution of chronic and severe inflammation.
OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a GPCR (G-Protein Coupled Receptor) target. Activation of ChemR23 provides a new mechanism against chronic inflammation by targeting both macrophages and neutrophils.
Under the terms of the agreement, AbbVie will obtain an exclusive worldwide license to develop, manufacture and commercialize OSE-230. OSE Immunotherapeutics will receive an upfront payment of $48 million and may receive up to an additional $665 million in development, regulatory and commercialization milestone payments. Additionally, OSE Immunotherapeutics may receive tiered royalties on worldwide net sales of OSE-230.
©2024 Boursier.com